Bayer aims for new Xarelto nod in Japan; Purdue recruits first chief commercial officer; Durata med wins FDA clearance;

> Bayer submitted its clot-fighter Xarelto for approval in Japan, to treat deep vein thrombosis and pulmonary embolism. Report

> Purdue Pharma tapped Saeed Motahari, formerly an AbbVie ($ABBV) VP of sales and marketing, to be its first chief commercial officer. Report

> Durata Therapeutics won FDA approval for its new drug to treat serious bacterial skin infections, Dalvance. Report

> The New York-based health communications group Chandler Chicco Companies, part of inVentiv Health, expanded its digital team with three new senior-level hires. Report

> Hungary's Richter agreed to buy a 51% stake in Mediplus, a Curacao-based company that promotes its products in Latin America. Report

And Finally... The use of antidepressants in England has risen faster than ever since the recession there boosted unemployment. Report

Suggested Articles

After showing Nucala could cut the rates of flares for hypereosinophilic syndrome, GSK is planning regulatory filings in 2020.

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Both IL-17A inhibitors have rolled out data showing they work in non-radiographic axial spondyloarthritis.